FTC Orange Book Move Signals New Pharma Patent Scrutiny
On Nov. 7, the Federal Trade Commission announced it is disputing the listing of more than 100 patents in the U.S. Food and Drug Administration's Approved Drug Products with Therapeutic Equivalence...To view the full article, register now.
Already a subscriber? Click here to view full article